LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 31

Search options

  1. Article ; Online: Letter to the Editor re: SGIM Telehealth Position Statement.

    Cho, Alex H / Cameron, Blake / Kheterpal, Meenal K

    Journal of general internal medicine

    2023  Volume 39, Issue 4, Page(s) 713

    Language English
    Publishing date 2023-12-12
    Publishing country United States
    Document type Letter
    ZDB-ID 639008-0
    ISSN 1525-1497 ; 0884-8734
    ISSN (online) 1525-1497
    ISSN 0884-8734
    DOI 10.1007/s11606-023-08569-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma.

    Fixsen, Emma / Patel, Jigar / Kheterpal, Meenal

    Cutis

    2022  Volume 110, Issue 4, Page(s) E11–E13

    MeSH term(s) Humans ; Adenocarcinoma of Lung/drug therapy ; Lung Neoplasms/drug therapy ; Nivolumab/adverse effects ; Scleroderma, Localized
    Chemical Substances Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2022-11-29
    Publishing country United States
    Document type Case Reports ; Letter
    ZDB-ID 391840-3
    ISSN 2326-6929 ; 0011-4162 ; 0151-9522
    ISSN (online) 2326-6929
    ISSN 0011-4162 ; 0151-9522
    DOI 10.12788/cutis.0637
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Sequential primary cutaneous follicle center lymphoma and marginal zone B-cell lymphoma arising in the same patient.

    Alvarez, Gabriella / Rodriguez-Homs, Larissa / Al-Rohil, Rami N / Kheterpal, Meenal / Fresco, Amber

    JAAD case reports

    2023  Volume 40, Page(s) 30–33

    Language English
    Publishing date 2023-08-03
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2834220-3
    ISSN 2352-5126
    ISSN 2352-5126
    DOI 10.1016/j.jdcr.2023.07.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Apremilast for the off-label treatment of lichenoid and interface dermatoses.

    Ravichandran, Surya / Kheterpal, Meenal K

    Journal of the American Academy of Dermatology

    2020  Volume 83, Issue 5, Page(s) 1489–1491

    MeSH term(s) Aged ; Female ; Humans ; Lichenoid Eruptions/drug therapy ; Middle Aged ; Off-Label Use ; Phosphodiesterase 4 Inhibitors/therapeutic use ; Retrospective Studies ; Thalidomide/analogs & derivatives ; Thalidomide/therapeutic use ; Young Adult
    Chemical Substances Phosphodiesterase 4 Inhibitors ; Thalidomide (4Z8R6ORS6L) ; apremilast (UP7QBP99PN)
    Language English
    Publishing date 2020-06-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2020.05.112
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy.

    Penny, Caitlin / Nath, Neel / Kheterpal, Meenal

    Journal of drugs in dermatology : JDD

    2022  Volume 21, Issue 6, Page(s) 668–670

    Abstract: Immune checkpoint inhibitors including programmed death protein 1 inhibitors show great therapeutic benefit for numerous advanced malignancies but can cause a spectrum of immune-related adverse events, with cutaneous toxicity being a common presentation. ...

    Abstract Immune checkpoint inhibitors including programmed death protein 1 inhibitors show great therapeutic benefit for numerous advanced malignancies but can cause a spectrum of immune-related adverse events, with cutaneous toxicity being a common presentation. This report includes two cases of lung adenocarcinoma treated with pembrolizumab that developed rare presentations of diffuse bullous lichenoid dermatitis involving >50% total body surface area. These cases were successfully treated in the outpatient setting with oral dexamethasone and minimal interruption of pembrolizumab therapy, a more conservative approach than current guidelines suggest. J Drugs Dermatol. 2022;21(6):668-670. doi:10.36849/JDD.6715.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological/adverse effects ; Dermatitis/drug therapy ; Humans ; Lung Neoplasms/drug therapy ; Outpatients
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; pembrolizumab (DPT0O3T46P)
    Language English
    Publishing date 2022-06-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2145090-0
    ISSN 1545-9616
    ISSN 1545-9616
    DOI 10.36849/JDD.6715
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Deep Learning in Dermatology: A Systematic Review of Current Approaches, Outcomes, and Limitations.

    Jeong, Hyeon Ki / Park, Christine / Henao, Ricardo / Kheterpal, Meenal

    JID innovations : skin science from molecules to population health

    2022  Volume 3, Issue 1, Page(s) 100150

    Abstract: Artificial intelligence (AI) has recently made great advances in image classification and malignancy prediction in the field of dermatology. However, understanding the applicability of AI in clinical dermatology practice remains challenging owing to the ... ...

    Abstract Artificial intelligence (AI) has recently made great advances in image classification and malignancy prediction in the field of dermatology. However, understanding the applicability of AI in clinical dermatology practice remains challenging owing to the variability of models, image data, database characteristics, and variable outcome metrics. This systematic review aims to provide a comprehensive overview of dermatology literature using convolutional neural networks. Furthermore, the review summarizes the current landscape of image datasets, transfer learning approaches, challenges, and limitations within current AI literature and current regulatory pathways for approval of models as clinical decision support tools.
    Language English
    Publishing date 2022-08-23
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 2667-0267
    ISSN (online) 2667-0267
    DOI 10.1016/j.xjidi.2022.100150
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma.

    Patel, Akash D / Ravichandran, Surya / Kheterpal, Meenal

    International journal of dermatology

    2021  Volume 61, Issue 1, Page(s) 118–124

    Abstract: Background: Hedgehog inhibitor therapy (HHIT) is considered first-line treatment for locally advanced, unresectable basal cell carcinoma (laBCC). HHIT often results in a partial response, which requires adjunctive therapy (AT) post HHIT. We present real- ...

    Abstract Background: Hedgehog inhibitor therapy (HHIT) is considered first-line treatment for locally advanced, unresectable basal cell carcinoma (laBCC). HHIT often results in a partial response, which requires adjunctive therapy (AT) post HHIT. We present real-world data for laBCCs undergoing HHIT ± AT.
    Methods: Retrospective review at Duke University from 11/01/2007 through 5/20/2020 revealed 13 patients treated with systemic HHIT (sonidegib or vismodegib) for laBCC.
    Results: Fourteen laBCCs were identified in 13 patients. LaBCCs were treated with sonidegib (n = 10, 71%) or vismodegib (n = 4, 29%) for a median (IQR) of 9.4 (9.3) or 9.8 (8.5) months, respectively. The median (IQR) follow-up time from HHIT initiation was 15.5 (8.7) months. Tumors were most often located on the trunk (43%), followed by head and neck (29%), extremities (21%), and orbit/periorbital area (7%). Nine laBCCs (64%) were treated with HHIT alone, of which five (36%) achieved complete response (CR), four (29%) achieved partial response (PR), and five (36%) achieved CR with combined HHIT and AT post-HHIT. Duration of HHIT treatment (IQR) was 7.5 (3.5) months in the 10 CR patients, versus 15.1 (6.3) months in the four PR patients (P = 0.024). Nine patients (69%) experienced adverse events from HHIT, most commonly ageusia/dysgeusia, muscle spasms, and alopecia.
    Conclusion: As a single institutional experience, we report 10/14 laBCCs (71%) with CRs without recurrence and 4/14 laBCCs (29%) with PRs with HHIT ± AT over median follow-up of 15.5 months. Longer follow-up and larger cohorts evaluating responses with HHIT followed by AT are needed to substantiate our findings.
    MeSH term(s) Anilides/adverse effects ; Antineoplastic Agents/adverse effects ; Carcinoma, Basal Cell/drug therapy ; Hedgehog Proteins ; Humans ; Retrospective Studies ; Skin Neoplasms/drug therapy
    Chemical Substances Anilides ; Antineoplastic Agents ; Hedgehog Proteins
    Language English
    Publishing date 2021-08-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 412254-9
    ISSN 1365-4632 ; 0011-9059 ; 1461-1244
    ISSN (online) 1365-4632
    ISSN 0011-9059 ; 1461-1244
    DOI 10.1111/ijd.15836
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors.

    Penny, Caitlin L / Quow, Krystina / Rundle, Chandler W / Al-Rohil, Rami N / Cardones, Adela R / Kheterpal, Meenal K / Fresco, Amber I

    The British journal of dermatology

    2022  Volume 187, Issue 2, Page(s) 275–276

    MeSH term(s) Antibodies, Monoclonal/adverse effects ; Fluorescent Antibody Technique, Direct ; Humans ; Immunoconjugates ; Skin Diseases
    Chemical Substances Antibodies, Monoclonal ; Immunoconjugates ; enfortumab vedotin (DLE8519RWM)
    Language English
    Publishing date 2022-05-24
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 80076-4
    ISSN 1365-2133 ; 0007-0963
    ISSN (online) 1365-2133
    ISSN 0007-0963
    DOI 10.1111/bjd.21239
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Radiation therapy for primary cutaneous γδ T-cell lymphoma: Case report and literature review.

    Kelsey, Chris R / Wang, Endi / Stefanovic, Alexandra / Kheterpal, Meenal

    JAAD case reports

    2019  Volume 5, Issue 7, Page(s) 582–586

    Language English
    Publishing date 2019-06-26
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2834220-3
    ISSN 2352-5126
    ISSN 2352-5126
    DOI 10.1016/j.jdcr.2019.05.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Teledermatology May Benefit Marginalized Populations: National and Institutional Trends during the COVID-19 Pandemic.

    Patel, Akash D / Rundle, Chandler W / Liu, Beiyu / Green, Cynthia L / Bailey-Burke, Christian L / Kheterpal, Meenal

    Dermatology and therapy

    2023  Volume 13, Issue 3, Page(s) 827–834

    Abstract: Introduction: Limited data exist regarding demographic-specific teledermatology (TD) utilization during the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to determine TD utilization trends during the pandemic.: Methods: A ... ...

    Abstract Introduction: Limited data exist regarding demographic-specific teledermatology (TD) utilization during the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to determine TD utilization trends during the pandemic.
    Methods: A retrospective cohort study for national and institutional populations was conducted. Patient encounters in the American Academy of Dermatology's DataDerm registry (DataDerm) were analyzed from 1 April 2020 through 30 June 2021. All dermatological patients seen by Duke University Health Systems (DUHS) were analyzed from 1 March 2020 through 30 April 2021. In-person clinic visits versus TD encounters (national and institutional) and no-show rates (institutional only) were collected for visit type (i.e., TD versus in-person), sex, race, age/generation, and in- versus out-of-state location (national only). TD utilization is defined as the cohort of interest using TD (e.g., females, whites) within a demographic group (i.e., sex, race) as a percentage of total TD users. This was compared with in-person utilization during the identical timeframe.
    Results: For US national data, 13,964,816 encounters were analyzed. Sex, race, age, and location each had a significant association with TD utilization (adjusted p < 0.001). For institutional data, 54,400 encounters were analyzed. Sex, race, and age had a significant association with TD utilization (adjusted p < 0.001). Both datasets revealed majority female populations for telehealth visits (DataDerm 66.0%; DUHS 61.7%). Non-white populations accounted for a higher percentage of TD utilizers (DataDerm 15.0%; DUHS 37.3%) when compared with in-person utilizers (DataDerm 11.7%; DUHS 22.3%). Younger patients utilized TD (DataDerm 63.6%; DUHS 62.6%) more than in-person services (DataDerm 26.3%; DUHS 43.8%). Institutional no-show rates between telehealth and in-person visits were lower for Black patients (11.8% versus 19.2%), other non-white races (10.6% versus 13.6%), and younger ages/generations (9.8% versus 12.8%), respectively. TD utilization decreased over time nationally as a percentage of total visits (2.9% versus 0.3%) in 2020 versus 2021, respectively.
    Conclusions and relevance: During the COVID-19 pandemic, certain populations (females, younger patients, non-white races) showed higher TD utilization. Understanding TD utilization trends is critical in defining the role of virtual care for improving universal care access, optimizing resources, and informing future healthcare models for all patient populations.
    Language English
    Publishing date 2023-02-08
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2680284-3
    ISSN 2190-9172 ; 2193-8210
    ISSN (online) 2190-9172
    ISSN 2193-8210
    DOI 10.1007/s13555-023-00900-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top